12.17
Novocure Ltd stock is traded at $12.17, with a volume of 2.02M.
It is up +7.70% in the last 24 hours and up +0.91% over the past month.
NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis, and other products and technologies for the treatment of Glioblastoma, Non-small cell lung cancer, and Pancreatic cancer. Geographically, the company derives the majority of its revenue from the United States and the rest from Germany, Japan, and other markets.
See More
Previous Close:
$11.30
Open:
$11.3
24h Volume:
2.02M
Relative Volume:
1.14
Market Cap:
$1.38B
Revenue:
$655.35M
Net Income/Loss:
$-136.23M
P/E Ratio:
-9.9566
EPS:
-1.2223
Net Cash Flow:
$-75.68M
1W Performance:
+12.79%
1M Performance:
+0.91%
6M Performance:
-14.17%
1Y Performance:
-26.06%
Novocure Ltd Stock (NVCR) Company Profile
Name
Novocure Ltd
Sector
Industry
Phone
44 (0)15 3475 6700
Address
NO. 4 THE FORUM, ST. HELIER
Compare NVCR vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
NVCR
Novocure Ltd
|
12.17 | 1.29B | 655.35M | -136.23M | -75.68M | -1.2223 |
|
ABT
Abbott Laboratories
|
101.56 | 175.59B | 44.33B | 6.50B | 7.40B | 3.717 |
|
SYK
Stryker Corp
|
341.24 | 132.47B | 25.12B | 3.25B | 4.28B | 8.3984 |
|
MDT
Medtronic Plc
|
87.10 | 113.14B | 35.48B | 4.64B | 5.41B | 3.582 |
|
BSX
Boston Scientific Corp
|
64.61 | 94.85B | 20.08B | 2.89B | 3.66B | 1.9391 |
|
EW
Edwards Lifesciences Corp
|
78.20 | 45.09B | 6.07B | 1.06B | 1.34B | 1.8063 |
Novocure Ltd Stock (NVCR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-25-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jul-08-25 | Initiated | Ladenburg Thalmann | Buy |
| Dec-02-24 | Upgrade | Evercore ISI | In-line → Outperform |
| Oct-16-24 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Nov-20-23 | Resumed | JP Morgan | Neutral |
| Aug-28-23 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Aug-08-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Aug-04-23 | Initiated | SVB Securities | Outperform |
| Jul-31-23 | Upgrade | Evercore ISI | Underperform → In-line |
| Jun-07-23 | Upgrade | Wedbush | Underperform → Neutral |
| May-16-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-17-23 | Downgrade | JP Morgan | Neutral → Underweight |
| Jan-06-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jan-05-23 | Reiterated | H.C. Wainwright | Buy |
| Nov-29-22 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Oct-24-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-05-22 | Downgrade | Evercore ISI | In-line → Underperform |
| May-16-22 | Initiated | H.C. Wainwright | Buy |
| Feb-08-22 | Initiated | Loop Capital | Buy |
| Feb-02-22 | Upgrade | Oppenheimer | Perform → Outperform |
| Jan-20-22 | Upgrade | Truist | Hold → Buy |
| Jan-03-22 | Upgrade | Evercore ISI | Underperform → In-line |
| Jul-01-21 | Downgrade | Mizuho | Buy → Neutral |
| Apr-14-21 | Downgrade | Wedbush | Neutral → Underperform |
| Jan-25-21 | Reiterated | Piper Sandler | Overweight |
| Sep-23-20 | Initiated | Northland Capital | Outperform |
| Sep-18-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Sep-17-20 | Downgrade | Truist | Buy → Hold |
| Jun-01-20 | Resumed | Oppenheimer | Perform |
| May-01-20 | Downgrade | Oppenheimer | Outperform → Perform |
| Apr-09-20 | Downgrade | Evercore ISI | In-line → Underperform |
| Mar-05-20 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jan-02-20 | Downgrade | Evercore ISI | Outperform → In-line |
| Jul-29-19 | Upgrade | SunTrust | Hold → Buy |
| Jul-26-19 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-26-19 | Downgrade | Wedbush | Outperform → Neutral |
| Mar-20-19 | Initiated | SunTrust | Hold |
| Nov-02-18 | Downgrade | Wells Fargo | Outperform → Market Perform |
| Jul-16-18 | Initiated | Evercore ISI | Outperform |
| Apr-18-18 | Reiterated | Mizuho | Buy |
| Feb-23-18 | Reiterated | Mizuho | Buy |
| May-24-17 | Upgrade | Wells Fargo | Market Perform → Outperform |
| Jul-29-16 | Reiterated | Wedbush | Outperform |
| Jan-19-16 | Initiated | Barclays | Underweight |
| Dec-02-15 | Initiated | Deutsche Bank | Hold |
View All
Novocure Ltd Stock (NVCR) Latest News
Is NovoCure’s (NVCR) Leadership Consolidation Clarifying Its Innovation Strategy Or Complicating Governance Signals? - simplywall.st
NovoCure Ltd (NVCR) Stock Up 5.4% and Still Undervalued -- GF Sc - GuruFocus
NVCR SEC FilingsNovocure 10-K, 10-Q, 8-K Forms - Stock Titan
Assessing NovoCure (NVCR) Valuation After Prolonged Share Price Weakness And Undervalued Narrative - simplywall.st
NovoCure Unifies Clinical And Innovation Roles As Market Discounts Persist - Sahm
NovoCure Ltd (NVCR) Stock Down 3.8% -- Now Undervalued? GF Score: 66/100 - GuruFocus
NovoCure Limited Increases Compensation for Dr. Uri Weinberg Upon Appointment as Chief Medical Officer - Minichart
Novocure increases executive compensation as Uri Weinberg takes on dual roles By Investing.com - Investing.com South Africa
Novocure increases executive compensation as Uri Weinberg takes on dual roles - Investing.com
NovoCure appoints Uri Weinberg as Chief Medical Officer alongside Chief Innovation Officer - TradingView — Track All Markets
NovoCure (NASDAQ: NVCR) boosts pay as Uri Weinberg assumes CMO duties - Stock Titan
NovoCure (BSP:N2VC34) Net Investment Income - GuruFocus
NovoCure (BSP:N2VC34) Other Assets for Insurance Companies - GuruFocus
NovoCure (BSP:N2VC34) Dividend Yield % : 0.00% (As of Apr. 09, 2026) - GuruFocus
NovoCure (BSP:N2VC34) Other Net Income (Loss) : R$0 Mil (TTM As of Dec. 2025) - GuruFocus
NovoCure (BSP:N2VC34) 6-1 Month Momentum % : N/A% (As of Apr. 09, 2026) - GuruFocus
NovoCure (BSP:N2VC34) Cash Flow from Discontinued Operations : R$0 Mil (TTM As of Dec. 2025) - GuruFocus
NovoCure (BSP:N2VC34) PEG Ratio : N/A (As of Apr. 09, 2026) - GuruFocus
NovoCure (BSP:N2VC34) Gross-Profit-to-Asset % : 49.36% (As of Dec. 2025) - GuruFocus
NovoCure (BSP:N2VC34) Shiller PE Ratio : (As of Apr. 09, 2026) - GuruFocus
NovoCure (BSP:N2VC34) Purchase Of Investment : R$-4,539 Mil (TTM As of Dec. 2025) - GuruFocus
NovoCure (BSP:N2VC34) Operating Income : R$-851 Mil (TTM As of Dec. 2025) - GuruFocus
NovoCure (BSP:N2VC34) Minority Interest : R$0.00 Mil (As of Dec. 2025) - GuruFocus
NovoCure (BSP:N2VC34) 3-1 Month Momentum % : N/A% (As of Apr. 09, 2026) - GuruFocus
NovoCure (BSP:N2VC34) Investments And Advances : R$0 Mil (As of Dec. 2025) - GuruFocus
NovoCure (BSP:N2VC34) Non Operating Income : R$0 Mil (TTM As of Dec. 2025) - GuruFocus
NovoCure (BSP:N2VC34) 1-Year Sharpe Ratio : N/A (As of Apr. 09, 2026) - GuruFocus
NovoCure (BSP:N2VC34) Retained Earnings : R$-7,040 Mil (As of Dec. 2025) - GuruFocus
NovoCure (BSP:N2VC34) Interest and Commission Paid - GuruFocus
NovoCure (BSP:N2VC34) Inventories, Other : R$-0 Mil (As of Dec. 2025) - GuruFocus
NovoCure (BSP:N2VC34) Forward Dividend Yield % : 0.00% (As of Apr. 09, 2026) - GuruFocus
NovoCure (BSP:N2VC34) Graham Number : R$N/A (As of Dec. 2025) - GuruFocus
NovoCure (BSP:N2VC34) PE Ratio (TTM) : At Loss (As of Apr. 09, 2026) - GuruFocus
NovoCure (BSP:N2VC34) Cyclically Adjusted PS Ratio : (As of Apr. 09, 2026) - GuruFocus
NovoCure (BSP:N2VC34) Other Long-Term Liabilities : R$0 Mil (As of Dec. 2025) - GuruFocus
NovoCure (BSP:N2VC34) Other Current Assets : R$106 Mil (As of Dec. 2025) - GuruFocus
NovoCure (BSP:N2VC34) Gross Property, Plant and Equipment : R$1,180 Mil (As of Dec. 2025) - GuruFocus
NovoCure (BSP:N2VC34) Total Operating Expense : R$3,550 Mil (TTM As of Dec. 2025) - GuruFocus
NovoCure (BSP:N2VC34) Purchase Of Business : R$0 Mil (TTM As of Dec. 2025) - GuruFocus
NovoCure (BSP:N2VC34) Sale Of Business : R$0 Mil (TTM As of Dec. 2025) - GuruFocus
NovoCure (BSP:N2VC34) Dividend Payout Ratio : 0.00 (As of Dec. 2025) - GuruFocus
NovoCure (BSP:N2VC34) Cyclically Adjusted Price-to-FCF : (As of Apr. 09, 2026) - GuruFocus
NovoCure (BSP:N2VC34) Net Policyholder Benefits/Claims - GuruFocus
NovoCure (BSP:N2VC34) Policyholder Funds - GuruFocus
BSP:N2VC34 EBITDA: R$-581 Mil | Possible Value Trap - GuruFocus
NovoCure (BSP:N2VC34) Goodwill : R$0 Mil (As of Dec. 2025) - GuruFocus
BSP:N2VC34 OCF Yield %: -3.95 | Possible Value Trap - GuruFocus
NovoCure (BSP:N2VC34) Other Operating Expense : R$-0 Mil (TTM As of Dec. 2025) - GuruFocus
BSP:N2VC34 EV-to-EBITDA: 0.72 | Possible Value Trap - GuruFocus
BSP:N2VC34 Accounts Payable: R$667 Mil | Possible Value Trap - GuruFocus
BSP:N2VC34 FCF Margin %: -13.13% | Possible Value Trap - GuruFocus
Novocure Ltd Stock (NVCR) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):